Summary
Ibogaine is a powerful alkaloid with unique psychedelic and dissociative properties used clinically for addiction treatment but carries significant cardiac risks including QT prolongation and arrhythmias. Medical supervision with cardiac monitoring is essential due to serious potential complications including death. It produces a two-phase experience: an initial visionary phase with intense visual phenomena lasting 4-8 hours, followed by a prolonged introspective phase. The substance is illegal in many countries including the United States (Schedule I). Pre-treatment cardiac screening is mandatory to assess for contraindications.
Dose Information
| ROA | Light | Common | Strong | Heavy |
|---|---|---|---|---|
| Oral BA ~40% | - | 15-22mg/kgofbodyweight | - | - |
Light
Common
Strong
Heavy
Onset, Duration & After-effects
| ROA | Onset | Peak | Offset | After Effects | Total |
|---|---|---|---|---|---|
| Oral | 1.0-3.0 hrs | 4.0-8.0 hrs | 8.0-24.0 hrs | 24.0-72.0 hrs | 24.0-30.0 hrs |
Tolerance
Build-up
not applicable — typically used as a single large dose
Reset
not applicable
Effects
Positive
- Stimulation
- Withdrawal suppression
- Mental/physical stimulation
Negative
- Nausea
- Ataxia
- Abnormal heartbeat
- Restlessness
- Sweating/chills
- Muscle tension
- Insomnia
- Decreased appetite
- Pupil constriction
Positive
- Analysis enhancement
- Introspection
- Emotion enhancement
- Catharsis
- Wakefulness
- Addiction suppression
- Euphoria
- Empathy
- Insight
Negative
- Memory suppression
- Dizziness
- Confusion
- Personal bias suppression
- Time distortion
- Change in perception
- Ego softening
Positive
- Brightened colour
- Enhanced tactile sensation
- Colour shifting
Negative
- Spatial disorientation
- Visual hallucinations
- Internal hallucination
- Autonomous entities
- Closed/Open eye visuals
- Drifting
- Visual distortions